Biogen (BIIB) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09062X1037
Biogen Inc. is a global company that focuses on discovering, developing, and delivering groundbreaking therapies for neurological and neurodegenerative diseases, not only in the United States and Europe but also in Germany, Asia, and various other international markets.
The company offers a wide range of treatments for various conditions, including multiple sclerosis (MS), Alzheimer's disease, spinal muscular atrophy, plaque psoriasis, and other autoimmune diseases. Some well-known products in their portfolio include TECFIDERA, VUMERITY, ADUHELM, and SPINRAZA.
In addition to its existing products, Biogen is actively involved in the development of new therapies for diseases like MS, Alzheimer's, dementia, Parkinson's, and genetic neurodevelopmental disorders. They have collaborations with several other pharmaceutical companies and are continuously working on advancing their product pipeline.
Established in 1978 and headquartered in Cambridge, Massachusetts, Biogen's mission is to transform the lives of patients suffering from debilitating diseases by providing innovative and effective treatment options. For more information, you can visit their official website here: https://www.biogen.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
BIIB Stock Overview
| Market Cap in USD | 29,298m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 1991-09-16 |
BIIB Stock Ratings
| Growth 5y | -2.22 |
| Fundamental | 0.34 |
| Dividend | - |
| Rel. Performance vs Sector | -4.40 |
| Analysts | 4.21/5 |
| Fair Price Momentum | 167.05 USD |
| Fair Price DCF | 237.76 USD |
BIIB Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
BIIB Growth Ratios
| Growth 12m | -33.88% |
| Growth Correlation 12m | -80% |
| Growth Correlation 3m | -81% |
| CAGR 5y | -3.20% |
| Sharpe Ratio 12m | -1.70 |
| Alpha vs SP500 12m | -51.89 |
| Beta vs SP500 5y weekly | 0.77 |
| ValueRay RSI | 17.69 |
| Volatility GJR Garch 1y | 39.34% |
| Price / SMA 50 | -10.08% |
| Price / SMA 200 | -20.76% |
| Current Volume | 1599.2k |
| Average Volume 20d | 1140.9k |
External Links for BIIB Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of April 20, 2024, the stock is trading at USD 194.38 with a total of 1,599,173 shares traded.
Over the past week, the price has changed by -1.92%, over one month by -11.09%, over three months by -22.24% and over the past year by -33.49%.
According to ValueRays Forecast Model, BIIB Biogen will be worth about 183.3 in April 2025. The stock is currently trading at 194.38. This means that the stock has a potential downside of -5.72%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 301.6 | 55.2% |
| Analysts Target Price | 330.8 | 70.2% |
| ValueRay Target Price | 183.3 | -5.72% |